Lake Street raised the firm’s price target on BioLife Solutions to $20 from $15 and keeps a Buy rating on the shares after the company announced Q4 revenue. While revenue was “marginally short of expectations,” line of sight into macro improvements and the impending sale of the freezer business “provide confidence in the longer-term financial profile” of the company, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLFS:
- BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue
- BioLife Solutions sees FY23 revenue $143.3M, consensus $144.37M
- BioLife Solutions sees Q4 revenue $32.7M, consensus $33.82M
- BioLife Solutions management to meet virtually with KeyBanc
- BioLife Solutions files $75M mixed securities shelf
